Bajrami, Ilirjana
Walker, Callum
Krastev, Dragomir B.
Weekes, Daniel
Song, Feifei
Wicks, Andrew J. http://orcid.org/0000-0002-9307-3262
Alexander, John http://orcid.org/0000-0003-3973-6501
Haider, Syed http://orcid.org/0000-0001-6685-5480
Brough, Rachel
Pettitt, Stephen J. http://orcid.org/0000-0003-3313-3857
Tutt, Andrew N. J. http://orcid.org/0000-0001-8715-2901
Lord, Christopher J. http://orcid.org/0000-0002-3226-0515
Funding for this research was provided by:
Cancer Research UK (C30061/A24439)
Breast Cancer Now
Article History
Received: 22 June 2021
Accepted: 6 October 2021
First Online: 8 November 2021
Competing interests
: A.J.N.T. reports honoraria from Pfizer, Vertex, Prime Oncology, Artios, honoraria and stock in InBioMotion, honoraria and financial support for research from AstraZeneca, Medivation, Myriad Genetics, Merck Serono. Travel expenses covered by AstraZeneca for any trial related meetings or trial commitments abroad. A.J.N.T. reports research funding from the ICR Rewards to Inventors scheme associated with patents for one of PARP inhibitors in BRCA1/2 associated cancers. C.J.L. makes the following disclosures: received research funding from: AstraZeneca, Merck KGaA, Artios. Received consultancy, SAB membership or honoraria payments from: Syncona, Sun Pharma, GLG, Merck KGaA, Vertex, AstraZeneca, Tango, 3rd Rock, Ono Pharma, Artios. Has stock in: Tango, Ovibio. C.J.L. is also a named inventor on patents describing the use of DNA repair inhibitors and stands to gain from the development as part of the ICR Rewards to Inventors scheme. The remaining authors declare no competing interests.